Sign in
TerminatedEarly phase 1

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

Key facts

Who runs it
University of Utah
Where
Salt Lake City, United StatesSee the site
Trial code
Status
Terminated
Phase
Early phase 1
People taking part
2 people enrolled
Started
31 Mar 2021
Ended
30 Jul 2024
Type of study
Interventional
Treatments tested
  • [18F]Fluoroestradiol (FES) PET/CT
Record updated
28 October 2024
Why it stopped
It was not feasible to perform FES PET/CT

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adults aged 18 years or greater
  • All patients or legal guardians are willing and able to sign written informed consent and HIPAA authorization in accordance with local and institutional guidelines
  • Enrolled on the FORESEE trial
  • Biopsy proven estrogen receptor positive breast cancer
  • Patient deemed refractory to all combinations of hormonal therapies by FORESEE trial investigators

Who cannot take part

  • Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion
  • Patients who require monitored anesthesia for PET/CT scanning
  • Patients who are too claustrophobic to undergo PET/CT scanning
  • Patients who are pregnant or currently breast feeding
  • Any patient that is medically unstable defined as a patient requiring inpatient hospitalization or needing evaluation at an acute care or urgent care facility at the time of imaging

Where in United States

  • Huntsman Cancer Institute at University of UtahSalt Lake City, United States

About the trial

What the trial wants to find out

This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide therapeutic decision making for functional precision oncology trials. The unique ability of FES-PET/CT to show absence of functional estrogen receptors throughout the entire body may improve confidence among research oncologists that an ER+ metastatic breast cancer patient is truly refractory to hormonal therapies which is a critical determination in the study design of the FORESEE trial.

The group in the trial

  • Treatment: all patientsTreatment being tested

    One session of \[18F\]FES PET/CT Imaging

    Treatment: [18F]Fluoroestradiol (FES) PET/CT

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE: Functional Precision Oncology for Metastatic Breast Cancer Feasibility Trial
Record updated
28 October 2024